%0 Journal Article %A Maxime Niesen %A Nicola Trotta %A Antoine Noel %A Tim Coolen %A Georges Fayad %A Gil Leurkin-Sterk %A Isabelle Delpierre %A Sophie Henrard %A Niloufar Sadeghi %A Jean-Christophe Goffard %A Serge Goldman %A Xavier De Tiège %T Structural and metabolic brain abnormalities in COVID-19 patients with sudden loss of smell %D 2020 %R 10.1101/2020.10.18.20214221 %J medRxiv %P 2020.10.18.20214221 %X Objectives Sudden loss of smell is a very common symptom of coronavirus disease 19 (COVID-19). This study characterizes the structural and metabolic cerebral correlates of dysosmia in patients with COVID-19.Methods Structural brain magnetic resonance imaging (MRI) and positron emission tomography with [18F]-fluorodeoxyglucose (FDG-PET) were prospectively acquired simultaneously on a hybrid PET-MR in twelve patients (2 males, 10 females, mean age: 42.6 years, age range: 23-60 years) with sudden dysosmia and positive detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on nasopharyngeal swab specimens. FDG-PET data were analysed using a voxel-based approach and compared with that of a group of healthy subjects.Results Bilateral blocking of the olfactory cleft was observed in six patients, while subtle olfactory bulb asymmetry was found in three patients. No MRI signal abnormality downstream of the olfactory tract was observed. Heterogeneous (decrease or increase) glucose metabolism abnormalities were observed in core olfactory and high-order neocortical areas. A modulation of regional cerebral glucose metabolism by the severity and the duration of COVID-19-related dysosmia was disclosed using correlation analyses.Conclusions This PET-MR study shows that sudden loss of smell in COVID-19 is not related to central involvement due to SARS-CoV-2 neuroinvasiveness. Loss of smell is associated with heterogeneous cerebral metabolic changes in core olfactory and high-order cortical areas likely related to combined processes of deafferentation and active functional reorganisation secondary to the lack of olfactory stimulation.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a special call COVID-19 funded by the Universite libre de Bruxelles, the Fonds Erasme (Brussels, Belgium) and the Fondation ULB (Brussels, Belgium). The PET-MR project at the CUB Hopital Erasme and Universite libre de Bruxelles is financially supported by the Association Vincotte Nuclear (AVN, Brussels, Belgium). Tim Coolen is Clinical Master Specialist applicant to a PhD at the Fonds de la Recherche Scientifique (FRS-FNRS, Brussels, Belgium). Xavier De Tiege is Postdoctorate Clinical Master Specialist at the FRS-FNRS (Brussels, Belgium).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Studies were carried out at the CUB Hopital Erasme (Brussels, Belgium). Participants contributed to the corresponding studies approved by the institutional Ethics Committee after written informed consent (References: P2020/204, CCB: B4062020000031; P2017/541, CCB: B406201734197).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDe-identified brain MRI and FDG-PET data can be shared upon reasonable request for scientific purpose and after approval of the CUB Hopital Erasme Ethics Committee and authorities. %U https://www.medrxiv.org/content/medrxiv/early/2020/10/20/2020.10.18.20214221.full.pdf